1. Home
  2. CIK vs PMN Comparison

CIK vs PMN Comparison

Compare CIK & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

N/A

Current Price

$2.37

Market Cap

134.4M

Sector

Finance

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$13.05

Market Cap

131.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CIK
PMN
Founded
N/A
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Finance/Investors Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.4M
131.5M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
CIK
PMN
Price
$2.37
$13.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$42.67
AVG Volume (30 Days)
426.4K
33.8K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.40
$0.29
52 Week High
$3.00
$27.40

Technical Indicators

Market Signals
Indicator
CIK
PMN
Relative Strength Index (RSI) 31.18 44.22
Support Level N/A $12.89
Resistance Level $2.57 $14.77
Average True Range (ATR) 0.02 1.21
MACD -0.00 -0.10
Stochastic Oscillator 22.22 21.36

Price Performance

Historical Comparison
CIK
PMN

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: